Novartis Cancer Unit To Pay $8M To Settle Securities Row

Law360, Los Angeles (February 11, 2014, 9:29 PM EST) -- Novartis AG subsidiary Genoptix Inc. will pay nearly $8 million to end a putative securities class action alleging the company misrepresented customer demand for diagnostic cancer testing and didn't disclose factors dragging down demand, according to a settlement stipulation filed Tuesday in California federal court.

Lead plaintiff City of Ann Arbor Employees’ Retirement System and Genoptix asked the court to preliminarily approve the settlement, which would provide $7.7 million plus interest to class members who bought Genoptix stock between July 2009 and June 2010.

“Absent the...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Construction Workers Pension Trust Fund v. Genoptix, Inc et al


Case Number

3:10-cv-02502

Court

California Southern

Nature of Suit

Securities/Commodities

Judge

Cathy Ann Bencivengo

Date Filed

December 6, 2010

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.